Home / Agenda

September 21–23, 2027

Three days across the full value chain.

Science and regulation set the foundation. Manufacturing and commercial strategy build the route to market. Partnering turns it into action.

Have a case study that belongs on this program?Share the evidence, operating lesson, or decision framework delegates should hear.
Submit a proposal

Program at a glance

Explore the program

Choose a day to follow the summit’s progression from evidence to market and partnership.

Day 01 focus

Science, regulatory & clinical foundations

Tuesday, September 21

  1. Registration and networking breakfast

    Networking

  2. Welcome and opening remarks

    Opening

  3. Opening keynote: The state of the global biosimilars market, 2027 and beyond

    Keynote

  4. Analytical similarity and totality of evidence: what regulators actually look for

    Panel

  5. Networking break and sponsor showcase

    Networking

  6. Interchangeability designations and their commercial impact on pharmacy substitution

    Session

  7. Networking lunch

    Networking

  8. Global regulatory harmonization: comparing FDA, EMA, PMDA, and CDSCO pathways

    Panel

  9. Clinical trial design for biosimilar development: efficient paths to approval

    Session

  10. Networking break and sponsor showcase

    Networking

  11. Emerging classes: GLP-1, ophthalmology, and next-generation insulin biosimilars

    Panel

  12. A former FDA official’s view on the next five years of biosimilar policy

    Fireside

  13. Day 1 closing remarks

    Closing

  14. Welcome reception

    Reception

Day 02 focus

Manufacturing, market access & commercial strategy

Wednesday, September 22

  1. Networking breakfast

    Networking

  2. Manufacturing at scale: what it takes to compete in biosimilars in 2027

    Keynote

  3. CDMO selection criteria and technology transfer best practices

    Panel

  4. Networking break and sponsor showcase

    Networking

  5. Quality systems, comparability protocols, and supply chain resilience

    Session

  6. Medicare Maximum Fair Price: what it means for biosimilar pricing and adoption

    Panel

  7. Networking lunch

    Networking

  8. Physician and patient adoption barriers: closing the gap between approval and uptake

    Session

  9. Patent litigation under the BPCIA: lessons from recent cases

    Panel

  10. Networking break and sponsor showcase

    Networking

  11. Licensing deal structures: case studies from recent transactions

    Panel

  12. Capital flows and deal trends in the biosimilars sector

    Briefing

  13. Day 2 closing remarks

    Closing

  14. Sponsor-hosted evening event

    Reception

Day 03 focus

Partnering day & forward outlook

Thursday, September 23

  1. Networking breakfast

    Networking

  2. How to make the most of partnering day

    Opening

  3. Structured one-on-one partnering meetings: pre-scheduled delegate matches

    Partnering

  4. Networking lunch

    Networking

  5. Structured one-on-one partnering meetings continued

    Partnering

  6. Networking break

    Networking

  7. The next five years of biosimilars: forward outlook

    Plenary

  8. Closing keynote and summit wrap-up

    Keynote

  9. PARITY 2027 closes

    Closing

Build the meetings around the program.

All full summit passes include access to the partnering platform.

Compare passesPartnering FAQ